These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 21775098)

  • 1. Upstream treatment of ST-segment elevation myocardial infarction: the role of glycoprotein IIb/IIIa inhibitors.
    Joyal D; Eisenberg MJ
    Can J Cardiol; 2011; 27(5):534-5. PubMed ID: 21775098
    [No Abstract]   [Full Text] [Related]  

  • 2. Tirofiban use with clopidogrel and aspirin decreases adverse cardiovascular events after percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials.
    Sethi A; Bahekar A; Doshi H; Bhuriya R; Bedi U; Singh S; Khosla S
    Can J Cardiol; 2011; 27(5):548-54. PubMed ID: 21871775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    Ernst NM; Suryapranata H; Miedema K; Slingerland RJ; Ottervanger JP; Hoorntje JC; Gosselink AT; Dambrink JH; de Boer MJ; Zijlstra F; van 't Hof AW
    J Am Coll Cardiol; 2004 Sep; 44(6):1187-93. PubMed ID: 15364318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial.
    Valgimigli M; Tebaldi M; Campo G; Gambetti S; Bristot L; Monti M; Parrinello G; Ferrari R;
    JACC Cardiovasc Interv; 2012 Mar; 5(3):268-77. PubMed ID: 22440491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term follow-up of tirofiban as alternative therapy for urgent surgery patients with an implanted coronary drug-eluting stent after ST-elevation myocardial infarction.
    Xia JG; Qu Y; Shen H; Liu XH
    Coron Artery Dis; 2013 Sep; 24(6):522-6. PubMed ID: 23900046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of pre-hospital glycoprotein IIb-IIIa inhibitors on angiographic outcome in STEMI patients who are candidates for primary PCI.
    Hermanides RS; van Werkum JW; Ottervanger JP; Breet NJ; Gosselink AT; van Houwelingen KG; Dambrink JH; Hamm C; ten Berg JM; van 't Hof AW;
    Catheter Cardiovasc Interv; 2012 May; 79(6):956-64. PubMed ID: 22162050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prehospital high-dose tirofiban in patients undergoing primary percutaneous intervention. The AGIR-2 study.
    El Khoury C; Dubien PY; Mercier C; Belle L; Debaty G; Capel O; Perret T; Savary D; Serre P; Bonnefoy E;
    Arch Cardiovasc Dis; 2010 May; 103(5):285-92. PubMed ID: 20619238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Spleen rupture in myocardial infarction after administration of GP IIb-IIIa-antagonists].
    Feldmann C; Deutsch HJ
    Dtsch Med Wochenschr; 2005 Jan; 130(1-2):29-30. PubMed ID: 15619171
    [No Abstract]   [Full Text] [Related]  

  • 9. Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardial infarction (ASSIST).
    Le May MR; Wells GA; Glover CA; So DY; Froeschl M; Marquis JF; O'Brien ER; Turek M; Thomas A; Kass M; Jadhav S; Labinaz M
    Circ Cardiovasc Interv; 2009 Aug; 2(4):330-8. PubMed ID: 20031736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R). Rationale for the study and protocol design.
    Valgimigli M; Campo G; de Cesare N; Vranckx P; Hamon M; Angiolillo DJ; Sabatè M; Ferrari F; Furgieri A; Tumscitz C; Repetto A; Colangelo S; Meliga E; Kubbajeh M; Parrinello G; Percoco G; Ferrari R
    Cardiovasc Drugs Ther; 2008 Aug; 22(4):313-20. PubMed ID: 18561010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single high-dose bolus tirofiban with high-loading-dose clopidogrel in primary coronary angioplasty.
    Bilsel T; Akbulut T; Yesilcimen K; Terzi S; Sayar N; Dayi SU; Akgoz H; Ergelen M; Ciloglu F
    Heart Vessels; 2006 Mar; 21(2):102-7. PubMed ID: 16550311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Harrington RA; Becker RC; Cannon CP; Gutterman D; Lincoff AM; Popma JJ; Steg G; Guyatt GH; Goodman SG
    Chest; 2008 Jun; 133(6 Suppl):670S-707S. PubMed ID: 18574276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycoprotein IIb/IIIa inhibitor (tirofiban) in acute ST-segment elevation myocardial infarction.
    Fang CC; Jao YT; Chen Y; Yu CL; Wang SP
    Angiology; 2009; 60(2):192-200. PubMed ID: 18445614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
    Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
    J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tirofiban optimizes platelet inhibition for immediate percutaneous coronary intervention in high-risk acute coronary syndromes.
    Ivandic BT; Kurz K; Keck F; Staritz P; Lehrke S; Katus HA; Giannitsis E
    Thromb Haemost; 2008 Oct; 100(4):648-54. PubMed ID: 18841288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction.
    Fu XH; Hao QQ; Jia XW; Fan WZ; Gu XS; Wu WL; Hao GZ; Li SQ; Jiang YF; Geng W
    Chin Med J (Engl); 2008 Mar; 121(6):522-7. PubMed ID: 18364139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The loading dose of clopidogrel in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty.
    Lin GM; Han CL
    Am J Emerg Med; 2010 Mar; 28(3):382-3. PubMed ID: 20223400
    [No Abstract]   [Full Text] [Related]  

  • 18. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).
    Bromberg-Marin G; Marin-Neto JA; Parsons LS; Canto JG; Rogers WJ;
    Am J Cardiol; 2006 Nov; 98(9):1125-31. PubMed ID: 17056312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different effects of tirofiban and aspirin plus clopidogrel on myocardial no-reflow in a mini-swine model of acute myocardial infarction and reperfusion.
    Yang YJ; Zhao JL; You SJ; Wu YJ; Jing ZC; Yang WX; Meng L; Wang YW; Gao RL
    Heart; 2006 Aug; 92(8):1131-7. PubMed ID: 16387825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials.
    Tricoci P; Newby LK; Hasselblad V; Kong DF; Giugliano RP; White HD; Théroux P; Stone GW; Moliterno DJ; Van de Werf F; Armstrong PW; Prabhakaran D; Rasoul S; Bolognese L; Durand E; Braunwald E; Califf RM; Harrington RA
    Circ Cardiovasc Qual Outcomes; 2011 Jul; 4(4):448-58. PubMed ID: 21712522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.